Entheon Biomedical Corp. announced a partnership with Divergence Neuro Technologies Inc. to research and develop N, N-Dimethyltryptamine ("DMT") biomarkers ("Biomarkers") and a predictive model of biomarker responses to drug dosage and delivery of DMT- based psychedelic therapeutic products (the "DMT Products") targeted to treat a number of different addiction and substance use disorders. Divergence will also develop a software platform that supports the tracking of EEG data during pre, intra, and post dosing using, among other prediction models, the DMT Biomarker Model. Entheon will utilize Divergence's expertise to consult on planning, research, and development of the DMT Biomarker Model and the Application to predict acute responses to DMT based on the analysis of EEG data. Divergence will lead the process of integrating EEG into Entheon's DMT-therapy platform with the ultimate goal of incorporating the technology for use by any clinics utilizing DMT products for the treatment of substance use disorders. The Application to be developed is a predictive analytics platform that can infer neuro-state change, based on EEG data, during the uptake of DMT while utilizing machine-learning and AI technology, leveraging Divergence's innovative brain mapping technology with the purpose of guiding drug dosage levels and delivery of DMT during the therapy process. The Application to be built using the DMT Biomarker Model, at its core, will be a platform that generates highly reliable predicative indicators relating to brain state change following the administration of DMT. The Application will rely on the real-time input of high-fidelity brainwaves to be collected from clinical trial participants and patients to provide feedback on the sychedelic-therapy experience. Beyond DMT, the Application will be used to aggregate and analyze datasets extending to other psychedelics and therapeutic compounds in order to develop profiles and biomarkers that will be used to inform and guide patient experience and outcomes.